ETR:MOR - MorphoSys Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €97.20 +1.85 (+1.94 %) (As of 05/22/2019 07:18 AM ET)Previous Close€95.35Today's Range€94.20 - €97.9052-Week Range€76.45 - €124.90Volume128,709 shsAverage Volume153,687 shsMarket Capitalization$3.07 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany. Receive MOR News and Ratings via Email Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolETR:MOR Previous Symbol CUSIPN/A CIKN/A Webhttp://www.morphosys.de/ Phone+49-89-899270Debt Debt-to-Equity Ratio8.65 Current Ratio7.75 Quick Ratio7.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$87.19 million Price / Sales35.20 Cash Flow€11.08 per share Price / Cash Flow8.77 Book Value€14.78 per share Price / Book6.58Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees329 Outstanding Shares31,578,400Market Cap$3.07 billion Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable MorphoSys (ETR:MOR) Frequently Asked Questions What is MorphoSys' stock symbol? MorphoSys trades on the ETR under the ticker symbol "MOR." When is MorphoSys' next earnings date? MorphoSys is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for MorphoSys. What price target have analysts set for MOR? 9 brokerages have issued 1-year target prices for MorphoSys' shares. Their predictions range from €56.00 to €125.00. On average, they anticipate MorphoSys' share price to reach €100.78 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for MorphoSys. What is the consensus analysts' recommendation for MorphoSys? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys. Has MorphoSys been receiving favorable news coverage? News headlines about MOR stock have trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MorphoSys earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of MorphoSys' key competitors? Some companies that are related to MorphoSys include Moderna Inc (NASDAQ) (MRNA), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), ProMetic Life Sciences (PLI), Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO) and Oxford BioMedica (OXB). What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Supernus Pharmaceuticals (SUPN), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Solaredge Technologies (SEDG), Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Galmed Pharmaceuticals (GLMD), Neurocrine Biosciences (NBIX) and Portola Pharmaceuticals (PTLA). Who are MorphoSys' key executives? MorphoSys' management team includes the folowing people: Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)Mr. Klaus De Wall, Head of Accounting & Tax What is MorphoSys' stock price today? One share of MOR stock can currently be purchased for approximately €97.20. How big of a company is MorphoSys? MorphoSys has a market capitalization of $3.07 billion and generates $87.19 million in revenue each year. MorphoSys employs 329 workers across the globe. What is MorphoSys' official website? The official website for MorphoSys is http://www.morphosys.de/. How can I contact MorphoSys? MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270. MarketBeat Community Rating for MorphoSys (ETR MOR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 190 (Vote Underperform)Total Votes: 428MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: The mechanics of the bid-ask spread in trading Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.